Could dropping aspirin cut bleeding in LVAD patients?
NCT ID NCT06655376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 128 people with advanced heart failure who have a HeartMate3 heart pump. All take warfarin to prevent clots, and half will also stop taking aspirin. The goal is to see if skipping aspirin lowers the risk of serious bleeding without raising the chance of dangerous clots or strokes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin and warfarin
What this could lead to
If successful, this could show that many LVAD patients can safely avoid aspirin, lowering their risk of serious bleeding without increasing clots.
What could go wrong
This is a relatively small Phase 4 trial (128 people) and only includes patients already stable on an LVAD for over 3 months, so results may not apply to everyone. Skipping aspirin might still raise clot risk in some individuals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLEEDING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Texas Health Science Center at Houston
RECRUITINGHouston, Texas, 77030, United States
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States